Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...
13hon MSN
Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...
BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.
Investing.com -- Eli Lilly and Company (NYSE:LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior year. The company also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback